cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas

S Hernandez, L Hernandez, S Bea, M Cazorla, PL Fernandez, A Nadal, J Muntane, C Mallofre, E Montserrat, A Cardesa, E Campo*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

73 Citations (Web of Science)


cdc25A, cdc25B, and cdc25C are a family of human phosphatases that activate the cyclin-dependent kinases at different points of the cell cycle. cdc25A and cdc25B have been shown to have oncogenic potential, and they have been identified as transcriptional targets of c-myc. To determine the role of cdc25 genes in the pathogenesis of human lymphomas and their possible correlation with c-myc deregulation, we have analyzed the expression of cdc25A, cdc25B, and cdc25C and c-myc genes in a series of 63 non-Hodgkin's lymphomas and 8 nonneoplastic lymphoid tissues. The mRNA levels of the three phosphatases in the nonneoplastic tissues were negative or negligible. cdc25B overexpression was detected in 35 tumors (56%), This overexpression was more frequently found in aggressive (81%) than in indolent lymphomas (36%; P <0,01), cdc25B overexpression was also significantly associated with a higher proliferative activity of the tumors. No cdc25B gene amplification or rearrangements were detected by Southern blot analysis. A biallelic EcoRI polymorphism of cdc25B gene was identified with a similar distribution in patients with lymphoma and in a normal population. cdc25A was overexpressed in three aggressive lymphomas, No detectable cdc25C mRNA levels were seen in any of the tumors. c-myc was overexpressed in 43% of tumors, and it correlated significantly with the presence of cdc25B up-regulation. Twenty-six of 35 (74%) lymphomas with high levels of cdc25B mRNA also showed c-myc overexpression, whereas 27 of 28 (96%) tumors without detectable or with very low cdc25B expression also had undetectable c-myc levels (P <0,0001), In addition, a significant linear correlation was found between the cdc25B and c-myc mRNA levels (r = 0,575, P <0.001). These findings suggest that cdc25B overexpression in non-Hodkin's lymphoma may participate in the pathogenesis of aggressive variants, and it may cooperate with c-myc oncogene in the development of these tumors.

Original languageEnglish
Pages (from-to)1762-1767
Number of pages6
JournalCancer Research
Issue number8
Publication statusPublished - 15 Apr 1998


  • GENE


Dive into the research topics of 'cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas'. Together they form a unique fingerprint.

Cite this